Schroders and Lloyds Banking in Talks on Wealth Arm Business
(Bloomberg) -- Schroders Plc and Lloyds Banking Group Plc said they are in talks to work closely on the wealth management business as the fund manager vies to win a separate, coveted 109 billion pound ($143 billion) mandate from the British lender.
The companies in their statements on Monday made no mention of the portfolio mandate.
Key Insights- Schroders is the front runner to win the right to manage the Lloyds portfolio though Blackrock Inc. isn't out of the running, people with knowledge of the matter told Bloomberg last week.
- The U.K. bank invited asset managers to bid for control of the portfolio, to replace Standard Life Aberdeen Plc. The asset manager is getting out of the insurance business and has said that Lloyds doesn't have the right to end the deal.
- Banks are expanding in wealth management to diversify their revenue streams and boost income as record-low interest rates squeeze margins.
Market Reaction
- Schroders shares have declined 15 percent this year, and those of Lloyds have fallen more than 13 percent.
Digging Deeper
- Lloyds will add its wealth management unit, which oversees 13 billion pounds ($17 billion) of assets, into a potential joint venture with Schroders, Sky News reported Sunday.
- Schroders is the front runner to win the mandate to manage Lloyds portfolio of assets, though rival BlackRock Inc. isn't out of the running, a person with knowledge of the matter said earlier this month.
To contact the reporter on this story: Ambereen Choudhury in London at achoudhury@bloomberg.net
To contact the editors responsible for this story: Michael J. Moore at mmoore55@bloomberg.net, Sree Vidya Bhaktavatsalam, Ross Larsen
©2018 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.